Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATPase family AAA domain-containing protein 3C (ATAD3C) is a mitochondrial membrane-associated ATPase in the AAA+ superfamily, sharing homology with ATAD3A and ATAD3B. While previously considered a pseudogene product, ATAD3C is now recognized as a protein expressed in human cells, localizing to the mitochondria where it influences the structure and function of the mitochondrial inner membrane. ATAD3C modulates ATP binding and hydrolysis, affecting the assembly of mitochondrial respiratory complexes and oxidative phosphorylation, often by negatively regulating the function of ATAD3A through dominant-negative interactions. Functional disturbances in ATAD3C expression can impact mitochondrial organization, cellular proliferation, ROS production, and are associated with mitochondrial diseases and developmental syndromes. No drugs are known to directly interact with ATAD3C, and it is not currently an established therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATPase family AAA domain-containing protein 3C (ATAD3C).